公开(公告)号：US12246025B2

公开(公告)日：2025-03-11

申请号：US16982008

申请日：2019-03-20

Applicant: Genmab A/S

Inventor： Reshma Abdulla Rangwala ,  Esther C. W. Breij ,  Sandra Verploegen ,  Oyewale O. Abidoye ,  Leonardo Viana Nicacio

IPC: C07K16/36 ,  A61K9/00 ,  A61K31/555 ,  A61K33/243 ,  A61K47/68 ,  A61P35/00

Abstract: The invention provides a platinum-based agent (e.g., carboplatin) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as bladder cancer and cervical cancer. The invention also provides compositions and kits comprising the platinum-based agent (e.g., carboplatin) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as bladder cancer and cervical cancer.

公开(公告)号：US20250066506A1

公开(公告)日：2025-02-27

申请号：US18596319

申请日：2024-03-05

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Patrick VAN BERKEL ,  Kristin STRUMANE ,  Aran Frank LABRIJN ,  Joost J. NEIJSSEN ,  Joyce I. MEESTERS ,  Paul PARREN ,  Janine SCHUURMAN

IPC: C07K16/32 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/68 ,  C07K16/10 ,  C07K16/28 ,  C07K16/46

Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.

公开(公告)号：US20250002600A1

公开(公告)日：2025-01-02

申请号：US18696689

申请日：2022-10-05

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Alexander MUIK ,  Kristina SCHÖDEL ,  Nora PENCHEVA ,  Maria N. JURE-KUNKEL ,  Ugur SAHIN ,  Sina FELLERMEIER-KOPF ,  Patricia GARRIDO CASTRO ,  Jordan BLUM ,  Friederike GIESEKE ,  Esther C. W. BREIJ ,  Lars GUELEN ,  Joost NEIJSSEN ,  Karsten BECKMANN ,  Claudia PAULMANN ,  Bart-Jan DE KREUK ,  Richard G. HIBBERT ,  Janine SCHUURMAN ,  Aran LABRIJN ,  Ivan KUZMANOV

IPC: C07K16/28 ,  A61K9/00 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention provides combination therapy using a binding agent that binds to human CD137 and to human PD-L1 in combination with a PD-1 inhibitor to reduce or prevent progression of a tumor or treating cancer.

公开(公告)号：US20240400685A1

公开(公告)日：2024-12-05

申请号：US18664757

申请日：2024-05-15

Applicant: GENMAB A/S

Inventor： Richard G. HIBBERT ,  Bolette BJERREGAARD ,  Søren S. JENSEN ,  César Filipe OLIVEIRA DA COSTA ,  Rohan O'DONNELL

IPC: C07K16/28 ,  C07K1/18 ,  C07K1/34

Abstract: The present disclosure provides highly purified epcoritamab compositions, which comprise a bispecific antibody that binds CD3 and CD20. In the highly purified compositions, impurities, such as epcoritamab protein variants, process-related impurities and/or product-related impurities, have been minimized or removed. Methods of preparing the highly purified epcoritamab compositions are also provided.

公开(公告)号：US20240392032A1

公开(公告)日：2024-11-28

申请号：US18617483

申请日：2024-03-26

Applicant: Genmab A/S

Inventor： David SATIJN ,  Esther C.W. Breij ,  Bart E.C.G. De Goeij ,  Kristel Kemper ,  Patrick Engelberts ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Dennis Verzijl ,  Sjeng Horbach ,  Paul Parren

IPC: C07K16/30 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00 ,  C12N15/79

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20240317881A1

公开(公告)日：2024-09-26

申请号：US18420021

申请日：2024-01-23

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Grietje ANDRINGA ,  Frank BEURSKENS ,  Janine SCHUURMAN ,  David P.E. SATIJN ,  Tahamtan AHMADI

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2896 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

Abstract: Antibody variants comprising one or more mutations in the Fc region, particularly anti-CD38 antibodies comprising a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino acid residues are numbered according to the EU index.

公开(公告)号：US20240301078A1

公开(公告)日：2024-09-12

申请号：US18500799

申请日：2023-11-02

Applicant: GENMAB A/S

Inventor： Brian ELLIOTT ,  Tahamtan AHMADI ,  Christopher W.L. CHIU ,  Esther C.W. BREIJ ,  Ida HIEMSTRA ,  Maria N. JURE-KUNKEL

IPC: C07K16/28 ,  A61K31/475 ,  A61K31/573 ,  A61K31/675 ,  A61K31/704 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/46

CPC classification number: C07K16/2887 ,  A61K31/475 ,  A61K31/573 ,  A61K31/675 ,  A61K31/704 ,  A61K39/3955 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/468 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).

公开(公告)号：US20240294661A1

公开(公告)日：2024-09-05

申请号：US18526959

申请日：2023-12-01

Applicant: Genmab A/S

Inventor： David SATIJN ,  Sandra VERPLOEGEN ,  Wim BLEEKER ,  Steen LISBY ,  Jan VAN DE WINKEL ,  Patrick VAN BERKEL ,  Paul PARREN

IPC: C07K16/30 ,  A61K45/06 ,  A61K47/68 ,  C07K16/36

CPC classification number: C07K16/30 ,  A61K45/06 ,  A61K47/6817 ,  A61K47/6849 ,  C07K16/36 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.

公开(公告)号：US20240252673A1

公开(公告)日：2024-08-01

申请号：US18451780

申请日：2023-08-17

Applicant: Genmab A/S

Inventor： Reshma A. RANGWALA ,  Steen LISBY

IPC: A61K47/68 ,  A61K9/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  A61P35/04 ,  C07K16/32 ,  A61K39/00

CPC classification number: A61K47/6869 ,  A61K9/0019 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6811 ,  A61P35/00 ,  A61P35/04 ,  C07K16/32 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/565

Abstract: The invention provides methods and compositions for treating cancer, such as advanced cervical cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., advanced cervical cancer).

公开(公告)号：US20240165226A1

公开(公告)日：2024-05-23

申请号：US18488634

申请日：2023-10-17

Applicant: GENMAB A/S

Inventor： Jan VAN DE WINKEL ,  Paul PARREN ,  Yvo GRAUS ,  Judith OPRINS ,  Michel DE WEERS ,  Martine VAN VUGT ,  Ole BAADSGAARD ,  Steen LISBY

IPC: A61K39/395 ,  A61K31/198 ,  A61K31/4439 ,  A61K31/573 ,  A61K31/69 ,  A61K45/06 ,  A61P19/02 ,  A61P35/00 ,  C07K16/28 ,  A61K39/00

CPC classification number: A61K39/3955 ,  A61K31/198 ,  A61K31/4439 ,  A61K31/573 ,  A61K31/69 ,  A61K39/39558 ,  A61K45/06 ,  A61P19/02 ,  A61P35/00 ,  C07K16/2896 ,  A61K2039/505 ,  C07K2317/34

Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.